exoASO NRAS
Alternative Names: exoASO-NRASLatest Information Update: 14 Mar 2022
At a glance
- Originator Codiak BioSciences
- Class Antineoplastics; Antisense oligonucleotides; Exosome therapies
- Mechanism of Action NRAS protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours